NCT00968409View on ClinicalTrials.gov

Assessment of Progesterone Receptors in Breast Carcinoma by Positron Emission Tomography (PET) Using Fluoro Furanyl Norprogesterone (FFNP)

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Breast Cancer
Interventions
RADIATION

PET

PET imaging following injection of F18-FFNP to image hormone receptor status in patients with newly diagnosed breast cancer

OTHER

Laboratory Testing

Blood and urine samples for standard laboratory testing and radioactive counts will be obtained during the imaging sessions. Testing will include: urinalysis, complete blood count, comprehensive metabolic panel, and progesterone levels

OTHER

Safety Testing

ECG tracings and vital signs (blood pressure, heart rate, body temperature and respiration rate) are obtained at several time points before, during and after the imaging sessions.

DRUG

F18-FFNP

injection of F18-FFNP

Trial Locations (1)

63110

Washington University / Barnes-Jewish Hospital, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT00968409 - Assessment of Progesterone Receptors in Breast Carcinoma by Positron Emission Tomography (PET) Using Fluoro Furanyl Norprogesterone (FFNP) | Biotech Hunter | Biotech Hunter